Apogee has successfully licensed exclusive rights to ABC294640 to RedHill Biopharma. Apogee looks forward to working closely with RedHill for late stage clinical development in many cancer and inflammatory indications.
Apogee completed enrollment on the initial safety trial for ABC294640 in advanced solid tumor cancer patients. Results showed that the ABC294640 safety profile correlated well to that observed in preclinical toxicology studies and that ABC294640 had an excellent pharmacokinetic profile that modulated the pharmacodynamic marker of circulating spingosine-1-phosphate as expected. The results from this trial support additional clinical trials in cancer focused more on efficacy of this promising drug.